Find Answers. Take Action.®

Your Essential Partner in Cancer Care

Colleen enjoys photography and has been living with cancer since 2014.

Foundation Medicine is transforming cancer care by providing patients, physicians and researchers with a deep understanding of the genomic mutations that drive cancer.


For Providers

Foundation Medicine’s proven portfolio of tests and services offers the quality and commitment you need to help guide treatment strategies for your advanced cancer patients.


For Biopharma & Research Partners

We can support you from initial discovery to launch of a new therapy with our global portfolio of tests and services and our scientific and regulatory experts to fit your specific needs. As a leader in companion diagnostic (CDx) approvals, we are your ideal partner to help make your next breakthrough a standard of care.


For Patients

Every cancer is unique. That’s why we are committed to providing specific genomic insights into your cancer to help your doctor guide a personalized care plan.

Proven Leadership

Our unique knowledge base, FoundationCore®, is one of the world's largest cancer genomic databases. It is designed to evaluate the genomic landscape across cancer types to better understand tumor biology, molecular biomarkers, and which treatments might work for which patients. This all helps researchers and biopharma companies develop new therapies, design better clinical trials, and advance precision medicine. 

Over 1 Million






Valuable Insights, Actionable Options

Our tests help to identify the genomic alterations driving a patient's cancer and match them with relevant targeted therapies, immunotherapies, and clinical trial options. We also provide decision support services and technology solutions to help support patient care. Learn more about our products and services

Patient Story

Treating cancer means more than just dealing with the disease; it also means treating the whole person. Christine Bray, ovarian cancer survivor, shares her journey to remission after obtaining a Foundation Medicine comprehensive genomic profiling test.


Actionable Insights Upfront

We understand that treatment planning for your cancer patients can be complex. That’s why we’re updating our FoundationOne CDx and FoundationOne Liquid CDx reports to pull the “Professional Services” summary section to the first page. This update will bring information for all reported biomarker and genomic findings and our new “Report Highlights” section upfront, to help you focus on the critical findings for your patients.

* Data on file, Foundation Medicine Inc., data as of Nov. 18, 2022.

Important Safety Information


FoundationOne CDx

FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit